Literature DB >> 22276271

Pituitary metastasis as a presenting manifestation of silent systemic malignancy: A retrospective analysis of four cases.

P R K Bhargav1.   

Abstract

Entities:  

Year:  2012        PMID: 22276271      PMCID: PMC3263189          DOI: 10.4103/2230-8210.91215

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.
Sir, It is an informative and a well-drafted attempt to take an endocrinological view of pituitary metastases from a distant primary.[1] But, I have few queries and observations to extend. First, most of the described points in conclusion such as short lag time, diabetes insipidus (DI), rapidly appearing sellar mass, etc., can occur in adenomas with hemorrhage, cysts, hypophysitis, and pseudotumours which are much common than pituitary metastasis (PM).[2-4] Second, metastases can occur in preexisting adenomas leading to a sudden increase in the size of tumor.[5] Though PM tends to involve neurohypophysis earlier than adenohypophysis, only one case had preoperative DI and two cases had postoperative DI, which can occur as a complication of any hypophyseal surgery. Third, another differential diagnosis in the first two cases can be the rarely encountered pituitary carcinoma.[6] As seen in the second case, PM is highly unlikely given the gland size and accessibility for a distant primary to metastasize. Fourth, what were the exact histopathological findings and was any immunohistochemistry done to strengthen the diagnosis of PM? Occassionally, the Ki-67 proliferation index and electron microscopic ultrastructural features matched between PM and primary are useful to have definitive diagnosis and prognostication.[7] The histopathological features alone may not be sufficient to differentiate between adenoma, carcinoma, and PM. Fifth, the isolated presentation of a systemic malignancy with PM could be due to referral bias or chronology of clinical documentation, as such cases are anecdotal to the best of our knowledge. Last, we have to be very critical in labeling a case as PM as clinically, radiologically, and biochemically, the overlap with other pituitary pathologies is significant and the prognostic difference is significant.
  7 in total

1.  Diabetes insipidus and lymphocytic hypophysitis.

Authors:  Shigehiro Katayama; Chizuko Yokota
Journal:  Intern Med       Date:  2003-10       Impact factor: 1.271

Review 2.  Metastasis within a pituitary adenoma presenting with bilateral abducens palsies: case report and review of the literature.

Authors:  E L Zager; E T Hedley-Whyte
Journal:  Neurosurgery       Date:  1987-09       Impact factor: 4.654

3.  Endoscopic endonasal transsphenoidal approach for pituitary adenomas: technical aspects and report of casuistic.

Authors:  Américo Rubens Leite dos Santos; Roberto Monteiro Fonseca Neto; José Carlos Esteves Veiga; José Viana; Nilza Maria Scaliassi; Carmen Lúcia Penteado Lancellotti; Paulo Roberto Lazarini
Journal:  Arq Neuropsiquiatr       Date:  2010-08       Impact factor: 1.420

4.  Empty sella, growth hormone deficiency and pseudotumour cerebri: effect of initiation, withdrawal and resumption of growth hormone therapy.

Authors:  I Francois; I Casteels; J Silberstein; P Casaer; F de Zegher
Journal:  Eur J Pediatr       Date:  1997-01       Impact factor: 3.183

5.  Pituitary carcinoma: a clinicopathologic study of 15 cases.

Authors:  P J Pernicone; B W Scheithauer; T J Sebo; K T Kovacs; E Horvath; W F Young; R V Lloyd; D H Davis; B L Guthrie; W C Schoene
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

Review 6.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

7.  Pituitary metastasis as a presenting manifestation of silent systemic malignancy: A retrospective analysis of four cases.

Authors:  P Dutta; Anil Bhansali; V N Shah; Rama Walia; S K Bhadada; S Paramjeet; A Pathak; K K Mukherjee; N Khandelwal
Journal:  Indian J Endocrinol Metab       Date:  2011-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.